The Future Of Nano Technology
- Alan Watts
- Anti-Aging Medicine
- David Sinclair
- Gene Medicine
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Hormone Replacement Therapy
- Human Genetic Engineering
- Human Reproduction
- Integrative Medicine
- Life Skills
- Longevity Medicine
- Medical School
- Nano Medicine
- Parkinson's disease
- Regenerative Medicine
- Stem Cell Therapy
- Stem Cells
- Global Cryonics Technology Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 – Industry News Releases
- To save koalas from fire, we need to start putting their genetic material on ice – The Conversation AU
- Have You Found Meaning in Life? Scientific Study Says the Answer Could Determine Health and Longevity – Good News Network
- How To Increase Longevity: One Diet Could Lower Risk Of Developing Disease – International Business Times
- Increase Longevity: Prevent Development Of Cancer By Regularly Consuming This Diet – International Business Times
- pharmacogenetics wikipedia
- after 20 years of hiring I refuse
- genome editing wikipedia
- can you work in regenerative medicine with a biochemistry major
- linda ronstadt illness 2016 supra nuclear palsy
- verywellfit com
- is this true Allergens in plants produced as a result of genetic engineering can be transferred to human as if humans eat that allergic food
- anti anxiety & nootropics
- Cul3 anxiety
- learned immortality medical
|Search Immortality Topics:|
Category Archives: Nano Medicine
Innovative Report on Nanomedicine Market with Focusing on Eminent Players- Nanosphere Inc.,Pfizer Inc.,Combimatrix Corp – Finance Daily Tribune
Global Nanomedicine Market research report from Crystal Market Research covers overview defines characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market share, trends and strategies for the Nanomedicine industry.The size section gives the revenues, covering both the historic data of the Nanomedicine market and forecasting the future. Drivers and restraints are studied with respect to external factors influencing the growth of the market.
The authors of the Nanomedicine report shed light on lucrative business prospects, prominent trends, regulatory situations, and price scenarios of the global Nanomedicine market. Importantly, the report gives a detailed analysis of macroeconomic and microeconomics factors impacting the growth of the global Nanomedicine market. It is divided into various sections and chapters to help with easy understanding of each and every aspect of the global Nanomedicine market.
Click Here To Access The Sample Report @https://www.crystalmarketresearch.com/report-sample/HC122205
Check Exclusive Discount on this report @https://www.crystalmarketresearch.com/check-discount/HC122205
To get this report at a profitable rate @ https://www.crystalmarketresearch.com/send-an-enquiry/HC122205
Sherry | APAC Marketing Division: Level 23-1, Premier Suite
Mont Kiara, 50480 Kuala Lumpur
Global Healthcare Nanotechnology Market 2019 Research by Business Analysis, Growth Strategy and Industry Development to 2024 – Hitz Dairies
The recently published research study entitled Global Healthcare Nanotechnology Market 2019 by Company, Regions, Type and Application, Forecast to 2024 comprehensively describes the market and forecasts it to portray a highly illustrious growth during the forthcoming years, i.e. from 2019 to 2024. The report contains primary analysis on the global Healthcare Nanotechnology market which highlights numerous facts such as development factors, business enhancement strategies, statistical growth, and financial status. With this study, the readers and clients can understand the market on a global scale. It specifies the regions that are expected to witness the fastest growth during the forecast period. It has uncovered rapid development in the upcoming years.
The global market report offers clear-cut information about the key business-giants, Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith & Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International, along with demand, sales, revenue generation, reliable product development, services, and also post-sale processes at the global level.
DOWNLOAD FREE SAMPLE REPORT: https://marketandresearch.biz/sample-request/96029
What Market Factors Are Explained In The Report?
Overall, the report presents an in-depth overview of the worldwide market which will help clients to make convincing decisions on the basis of the prediction chart. The research is provided for leading growth status, including developments, segmentation, landscape analysis, product types, and applications. It proves to be an essential document for every market enthusiast, policymaker, investor, and player. In-depth information on the leading drivers and constraints of the Healthcare Nanotechnology industry is also presented in this report. In this report, the market has been examined on the basis of the assessment of production ability, different market players, and the manufacturing chain of the market across the world, and regional analysis.
For product type segment, this report listed the main product type of the market: Nanomedicine, Nano Medical Devices, Nano Diagnosis, Other
For end use/application segment, this report focuses on the status and outlook for key applications: Anticancer, CNS Product, Anti-infective, Other
Regionally, this report categorizes the production, apparent consumption, export and import of Healthcare Nanotechnology in North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa).
Points Covered Comprehensively In The Market Report:
Moreover, key aspects covered in this report include market growth, market demands, business strategies, consumption volume, and industry cost structure during the forecast period 2019-2024. Using Porters five-force method, the report analyzes the Healthcare Nanotechnology market. It helps to understand the business situation by examining industry components such as buyers and risk of substitutes, the challenge to new entrants, and industrial rivalry.
Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (firstname.lastname@example.org), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.
Fatima Aouidat,1 Sarah Boumati,2 Memona Khan,1 Frederik Tielens,3 Bich-Thuy Doan,2 Jolanda Spadavecchia1
1CNRS, UMR 7244, CSPBAT, Laboratory of Chemistry, Structures and Properties of Biomaterials And Therapeutic Agents University Paris 13, Sorbonne Paris Cit, Bobigny, France; 2UTCBS Chimie ParisTech University Paris Descartes - CNRS UMR 8258 INSERM U1022 Equipe Synthesis, Electrochemistry, Imaging and Analytical Systems for Diagnostics SEISAD, Paris, France; 3General Chemistry (ALGC), Vrije University of Brussel (Free University Brussels-VUB), Brussel, Belgium
Correspondence: Jolanda Spadavecchia Email email@example.com
Introduction: The development of biopolymers for the synthesis of Gd(III) nanoparticles, as therapeutics, could play a key role in nanomedicine. Biocompatible polymers are not only used for complex monovalent biomolecules, but also for the realization of multivalent active targeting materials as diagnostic and/or therapeutic hybrid nanoparticles. In this article, it was reported for the first time, a novel synthesis of Gd(III)biopolymerAu(III) complex, acting as a key ingredient of core-shell gold nanoparticles (Gd(@AuNPs).Material and methods: The physical and chemical evaluation was carried out by spectroscopic analytical techniques (Raman spectroscopy, UV-visible and TEM). The theoretical characterization by DFT (density functional theory) analysis was carried out under specific conditions to investigate the interaction between the Au and the Gd precursors, during the first nucleation step. Magnetic features with relaxivity measurements at 7T were also performed as well as cytotoxicity studies on hepatocyte cell lines for biocompatibility studies. The in vivo detailed dynamic biodistribution studies in mice to characterize the potential applications for biology as MRI contrast agents were then achieved.Results: Physicalchemical evaluation confirms the successful design and reaction supposed. Viabilities of TIB-75 (hepatocytes) cells were evaluated using Alamar blue cytotoxic tests with increasing concentrations of nanoparticles. In vivo biodistribution studies were then accomplished to assess the kinetic behavior of the nanoparticles in mice and characterize their stealthiness property after intravenous injection.Conclusion: We demonstrated that Gd@AuNPs have some advantages to display hepatocytes in the liver. Particularly, these nanoconjugates give a good cellular uptake of several quantities of Gd@NPs into cells, while preserving a T1 contrast inside cells that provide a robust in vivo detection using T1-weighted MR images. These results will strengthen the role of gadolinium as complex to gold in order to tune Gd(@AuNPs) as an innovative diagnostic agent in the field of nanomedicine.
Keywords: Gd-gold complex, theoretical study, MRI, relaxivity, biodistribution
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
See the original post here:
Design and Synthesis of Gold-Gadolinium-Core-Shell Nanoparticles as Co | IJN - Dove Medical Press
This month, a paper published by University researchers Richard Terek and Qian Chen highlighted a potential nanotechnology therapy that targets chondrosarcoma, a rare type of bone cancer. Using nanoparticles, the team effectively delivered therapies directly into tumor cells and observed decreases in tumor volume and prolonged survival in mouse models.
Chondrosarcoma currently has no FDA approved treatments. The complex makeup of these cancer cells makes them uniquely difficult to treat. Specifically, one challenge to (drug) delivery in chondrosarcoma is the negatively charged proteoglycan-rich extracellular matrix that needs to be penetrated to reach the tumor cells, according to the study.
Terek, the chief of musculoskeletal oncology at Rhode Island Hospital, an orthopedic oncology surgeon with the Lifespan Cancer Institute and a professor of orthopedic surgery at Warren Alpert, studies chondrosarcoma and collaborated with Chen, a molecular and nano-medicine researcher, director of the NIH-funded Center of Biomedical Research Excellence in Skeletal Health and Repair at Rhode Island Hospital and a professor of orthopedic research and medical science, on this study. The pair aimed to develop a nanopiece delivery platform capable of penetrating the convoluted chondrosarcoma matrix.
We develop nanomaterial (that) we call nanopieces and we found that it can deliver nucleic acid therapeutics to tissues that normally are very difficult to be penetrated, Chen said.
In addition to getting drugs to the tumor tissue, the researchers also studied the biology of how chondrosarcoma spreads. The other thing is we dont totally understand what drives cancer cells to metastasize. That part of the work involves trying to disentangle which types of pathways have gone awry, Terek said.
The underlying principle of the therapy is that miRNA, short 21-nucleotide sequences, are overexpressed in chondrosarcoma tumor cells. These miRNA end up functioning in a way similar to oncogenes, genes which drive cancer formation, by indirectly affecting other genes in the cancer pathway.
Tereks work over the past decade has culminated in the identification of the cancer-causing, or oncogenic, miRNA involved in chondrosarcoma formation. That process involved microarray analysis of primary human tumor tissues. We used a variety of screening techniques to identify which miRNA were overexpressed in tumors, Terek said.
These detrimental effects of the oncogenic miRNA can be prevented by synthesizing a molecule of the opposite sequence of nucleotides. Once delivered into the cell with the nanoparticles it will counteract and annihilate the overexpressed miRNA Terek said.
Once the target miRNA was identified, the small, opposing sequence of RNA needed to be delivered, a process that is normally very difficult because of the charge and structure of the matrix formed by the tumor. What we do in the lab is formulate this nanomaterial specifically for penetrating into the matrix, Chen said.
The laws kind of break down when you get to these nano levels. At the nano level, these particles somehow get through the cell wall and into the cell, even though the cell wall is classically thought of as this impenetrable structure around the cell, Terek said.
The nanomaterial delivery vehicle is composed of a small molecule, weighing about 400 daltons, which assembles into a nanotube structure that contains RNA. The molecule itself is biomimetic. Its half composed of nucleic bases and half of the molecule is amino acids, so its fused together. Because of that it also has a very low level of cell toxicity, Chen said. The nanoparticle is designed to be comparable to a natural biological structure, enabling the particle to be generally accepted by cells, so it can enter and affect them.
In previous studies, Chens lab has shown successful use of nanoparticle therapy in the treatment of multiple other diseases, including rheumatoid arthritis. Recently, they also received a grant from the National Institutes of Health funding research on the treatment of Alzheimers disease using a similar nanopiece delivery system that can traverse the blood brain barrier.
In further developing this drug therapy, Terek said one possibility is to combine multiple miRNA sequences with these nanoparticles to impact more pathways and get maximal inhibition of tumor spread. This involves both counteracting overexpressed miRNA, and restoring beneficial cancer suppressor miRNAs to combine multiple therapeutics with one dose of the nanoparticles.
Another potential approach is to pair the miRNA therapy with other cancer drug therapies. Since some miRNAs prevent the effective use of typical cancer treatment drugs, this approach can be used to reverse drug resistance, allowing for the use of conventional therapies, like chemotherapy.
In order for nanoparticle therapy development to succeed, investors, pharmaceutical companies, biotech companies and other collaborators need to give time and money to projects like this, Chen said. As far as moving it into the clinic, thats always a big hurdle, Terek said. One intermediate step the team might take is to collaborate with veterinarians allowing them to incorporate their treatment method beyond mouse models.
Brown and Lifespan have helped establish a startup called NanoDe so that we can continue the process, Chen said. Moving forward, the team will continue to work on collaborating with other researchers and developers to advance this drug therapy for chondrosarcoma.
Triple Negative Breast Cancer Treatment Market Analyzed by Business Growth, Development Factors and Future Prospects – chronicles24
Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer. Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints. These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the globaltriple-negative breast cancer treatment marketrevenue to cross US$ 720 Mn by 2026 from an estimated valuation of just under US$ 505 Mn in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.
Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs. Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare. The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care. A projected cost reduction to the tune of more than 30% 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer. This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.
Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market
Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer. Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market. Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities. This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.
Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market
One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy. Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market. Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.
Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer. Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.
Washington D.C: Researchers used nanoparticles to identify the presence of deadly microbes present on medical devices, like catheters, and make them infection-free.
This study was conducted as an interdisciplinary collaboration between microbiologists, immunologists, and engineers led by Dr Simon Corrie from Monash University's Department of Chemical Engineering and Professor Ana Traven from the Monash Biomedicine Discovery Institute (BDI).
It was recently published in the American Chemical Society journal ACS Applied Interfaces and Material.
Candida albicans, a commonly found microbe, can turn deadly when it colonises on devices such as catheters implanted in the human body.
The microbe forms a biofilm when it colonises using, for example, a catheter as a source of infection. It then spreads into the bloodstream to infect internal organs.
"The mortality rate in some patient populations can be as high as 30 to 40 per cent even if you treat people. When it colonises, it's highly resistant to anti-fungal treatments," Professor Traven said.
"The idea is that if you can diagnose this infection early, then you can have a much bigger chance of treating it successfully with current anti-fungal drugs and stopping a full-blown systemic infection, but our current diagnostic methods are lacking. A biosensor to detect early stages of colonisation would be highly beneficial," added Professor Traven.
The researchers investigated the effects of organosilica nanoparticles of different sizes, concentrations and surface coatings to see whether and how they interacted with both C. Albicans and with immune cells in the blood.
They found that the nanoparticles bound to fungal cells, but were non-toxic to them.
"They don't kill the microbe, but we can make an anti-fungal particle by binding them to a known anti-fungal drug," Professor Traven said.
The researchers also demonstrated that the particles associated with neutrophils -- human white blood cells -- in a similar way as they did with C. Albicans, remaining noncytotoxic towards them.
"We've identified that these nanoparticles, and by inference a number of different types of nanoparticles, can be made to be interactive with cells of interest," Dr Corrie said.
"We can actually change the surface properties by attaching different things; thereby we can really change the interactions they have with these cells -- that's quite significant," added Dr Corrie.
Dr Corrie said while nanoparticles were being investigated in the treatment of cancer, the use of nanoparticle-based technologies in infectious diseases lags behind the cancer nanomedicine field, despite the great potential for new treatments and diagnostics.
View original post here:
Study finds way to make medical equipment infection-free - ETHealthworld.com